Sona Asset Management US LLC Has $4.99 Million Stock Holdings in Drugs Made In America Acquisition II Corp. $DMII

Sona Asset Management US LLC lifted its stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) by 66.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 500,000 shares of the company’s stock after acquiring an additional 200,000 shares during the quarter. Sona Asset Management US LLC’s holdings in Drugs Made In America Acquisition II were worth $4,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in DMII. Geode Capital Management LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter valued at approximately $265,000. Virtu Financial LLC acquired a new position in shares of Drugs Made In America Acquisition II in the 4th quarter worth approximately $317,000. ABC Arbitrage SA bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at $396,000. Deltec Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth $495,000. Finally, Royal Bank of Canada acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth $655,000.

Drugs Made In America Acquisition II Stock Performance

Drugs Made In America Acquisition II stock opened at $10.10 on Monday. Drugs Made In America Acquisition II Corp. has a 52-week low of $9.86 and a 52-week high of $10.11. The stock’s 50 day simple moving average is $10.08.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on DMII shares. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Drugs Made In America Acquisition II currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.